For patients with the localized Ewing's sarcoma family of tumors (ESFT), first-line multimodal treatment, including intensive multi-agent chemotherapy, local radiation therapy and surgery, produces 70-75% of the long-term survival rate.
1,2 However, once patients relapse, there is no effective treatment that yields a 5-year survival rate exceeding 20%, even with high-dose chemotherapy (HDC) with autologous stem cell rescue. 3, 4 Therefore, a new and more effective treatment approach is clearly needed for this population. Several reports have described patients with ESFT who had bone marrow metastases and underwent allogeneic SCT instead of autologous SCT, 5 including a rare patient who exhibited evidence of a graftversus-tumor (GVT) effect. 6 To accumulate further knowledge, we report the case of a patient with recurrent ESFT who responded to allogeneic SCT from a sibling donor. A unique aspect of this case was that the manifestation of the GVT effect differed in different organs, with involvement of central nervous system (CNS) and non-CNS lesions. The GVT effect is rare in CNS diseases.
A 28-year-old woman was diagnosed with ESFT of the right chest wall. The tumor size was 10 Â 11 Â 8 cm and no metastases were shown on computed tomography (CT) or bone scans. Histology revealed small, round cells positive for the cell-surface glycoprotein CD99 and negative for desmin, myoD1, S100 protein, CD45 and CD30. Primary treatment comprised of two courses of chemotherapy with vincristine, doxorubicin and cyclophosphamide (VDC), followed by two courses of ifosfamide, and then HDC with thiotepa 300 mg/m 2 for 2 days and etoposide 300 mg/m 2 for 3 days with autologous peripheral blood stem cell rescue. Local radiation therapy with 50 Gy X-ray was also administered. The patient remained well without evidence of recurrent disease until 20 months after the autologous SCT, when she presented with chest pain and a recurrent tumor in the original site was observed on CT scanning (Figure 1a) . After four courses of re-induction chemotherapy, including one course of VDC, one course of ifosfamide and etoposide (IE), and two courses of irinotecan, and HDC consisting of etoposide 200 mg/m 2 for 4 days and melphalan 90 mg/m 2 for 2 days with autologous peripheral blood stem cell rescue, she achieved partial remission (Figure 1b) . The patient then entered a phase I/II clinical trial of reduced-intensity allogeneic SCT. After preconditioning with busulfan (4 mg/kg/day, orally from day À4 to day À3) and fludarabine (30 mg/m 2 /day, intravenously from day À8 to day À3), peripheral blood cells containing 2.4 Â 10 6 /kg CD34 þ cells from her HLAmatched sister were infused. Prophylactic immunosuppression with cyclosporine-A was started on day À1. Her post transplant course was uncomplicated, except for transient grade 1 GVHD of the skin, which began on day þ 64 and resolved by day þ 67 without any specific treatment. Cyclosporine-A was tapered from day þ 70 and discontinued on day þ 106. A CT scan taken 1 month after the allogeneic SCT when the tumor size was almost unchanged (Figure 1c ), but 4 months later, there was 50% reduction of the apical tumor (Figure 1d ). CR was confirmed at 8 months (Figure 1e) . The patient had headache and was found to have CNS disease on magnetic resonance imaging at 14 months. She died of the disease 5 months after the second relapse. The patient relapsed after initial treatment including HDC with autologous stem cell support, but thereafter, the tumor disappeared coincidently with the occurrence of GVHD, and at least for the primary lesion, the regression period exceeded the period of initial remission. Hence, a graft-versus-ESFT effect seems likely.
In this case, we followed the patient mainly by CT scanning. Although the CT findings showed the tumor status fairly well, they could not provide information regarding viability of the residual tumor. In this regard, PET scanning would be very helpful.
Interestingly, although the GVT effect was exerted in the primary lesion in the chest wall, it was not effective for the prevention of CNS recurrence in this case. The speculated reason for this observation is that the CNS is essentially an immunologically privileged site and theoretically, donor-derived immunocompetent cells carrying the GVT effect mechanism cannot cross the blood-brain barrier. 7 Hence, the application of additional therapeutic intervention to the CNS might become necessary after any systemic manifestations of a GVT effect. 
